Although it is still a relatively new field (ALK mutations in NSCLC were discovered in 2007 [57] and crizotinib was granted accelerated approval in 2011), ALK inhibitors can be given to lung cancer patients on a biomarker-based approach. This evidence concerns the gene ALK and lung carcinoma.